The tobacco industry settled one of several lawsuits that have been brought against it by various state governments and health plans.
The tobacco industry settled one of several lawsuits that have been brought against it by various state governments and health plans.
Blue Cross and Blue Shield of Minnesota, which was the first health plan in the country to file against the tobacco industry back in August 1994, will receive $469 million over a period of five years. The settlement is $9 million more than what the company sought.
The settlement also covers past and future liabilities for Blue Cross's fully insured members, as well as all of Blue Cross's legal fees.
"This is the beginning of the end of the tobacco epidemic that has devastated so many lives," said Andy Czajkowski, the company's CEO. "This settlement provides for significant public health initiatives and tobacco industry reforms that will forever change the way big tobacco does business in Minnesota."
The settlement included several public health provisions. It bans marketing tobacco products to children, bans promotional items that bear the names of cigarette brands, bans direct mailings from cigarette manufacturers into Minnesota and bans cigarette billboard advertising within Minnesota.
Other reform provisions include public access to 33 million internal tobacco industry documents in Minneapolis and Guilford, England; and halt of operations at the Council for Tobacco Research. The tobacco industry will be responsible for costs associated with these reform provisions.
Blue Cross announced that it will use a share of the settlement's proceeds to fund research into more effective tobacco prevention methods, new clinical treatments and cessation programs. It will also use some proceeds to make cessation programs more available to its members.
Blue Cross and Blue Shield of Minnesota insures more than 1.8 million plan members. It is Minnesota's oldest and largest health plan. PR
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
The Transformative Role of Medical Information in Customer Engagement
October 3rd 2024Stacey Fung, Head of Global Medical Information at Gilead Lifesciences, delves into the evolving role of Medical Information (MI) in the pharmaceutical industry. Covering key topics like patient engagement through omnichannel strategies, combating misinformation, and leveraging AI to enhance medical inquiries, the conversation with Stacey highlights MI's critical role in ensuring patient safety and supporting drug development. She also shares her professional journey and tidbits for early career professionals on professional development.
To Tackle the Plastic Waste Crisis in Pharma, Here’s Where to Start
October 30th 2024By demonstrating big advancements in recycling, pharma companies will be much more likely to attract shareholders and other investors, giving themselves a leg up in the competition to lead the biopharmaceutical industry well into the future.